相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz et al.
LANCET (2019)
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project
Monica Bellei et al.
HAEMATOLOGICA (2018)
Current status and progress of lymphoma management in China
Yuankai Shi
INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)
NCCN Guidelines® Insights T-Cell Lymphomas, Version 2.2018 Featured Updates to the NCCN Guidelines
Steven M. Horwitz et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2018)
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project
Monica Bellei et al.
HAEMATOLOGICA (2018)
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
Yuankai Shi et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
New Frontiers in the Pathobiology and Treatment of Cancer Regimen-Related Mucosal Injury
Marika Cinausero et al.
FRONTIERS IN PHARMACOLOGY (2017)
Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma
Dai Maruyama et al.
CANCER SCIENCE (2017)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States
Scott V. Adams et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial
Francine Foss et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma
Y. Shi et al.
ANNALS OF ONCOLOGY (2015)
Peripheral T-cell lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
F. d'Amore et al.
ANNALS OF ONCOLOGY (2015)
Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
Steven M. Horwitz et al.
BLOOD (2014)
Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry
Fredrik Ellin et al.
BLOOD (2014)
Peripheral T cell lymphoma in Asia
Sanghui Park et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2014)
Pralatrexate Pharmacology and Clinical Development
Enrica Marchi et al.
CLINICAL CANCER RESEARCH (2013)
Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
Vivien Mak et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Distribution of Lymphoid Neoplasms in China Analysis of 4,638 Cases According to the World Health Organization Classification
Jian Sun et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2012)
Subtype distribution of lymphomas in Southwest China: Analysis of 6,382 cases using WHO classification in a single institution
Qun-Pei Yang et al.
DIAGNOSTIC PATHOLOGY (2011)
Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
Owen A. O'Connor et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
分享论文
